These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 27155023)

  • 1. Treatment outcome variation between depression symptom combinations in the STAR*D study.
    Olbert CM; Rasmussen A; Gala GJ; Tupler LA
    J Affect Disord; 2016 Sep; 201():1-7. PubMed ID: 27155023
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes in depression subtypes for women during treatment with citalopram: a latent transition analysis.
    Ulbricht CM; Dumenci L; Rothschild AJ; Lapane KL
    Arch Womens Ment Health; 2016 Oct; 19(5):769-78. PubMed ID: 26802021
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in Depression Subtypes Among Men in STAR*D: A Latent Transition Analysis.
    Ulbricht CM; Dumenci L; Rothschild AJ; Lapane KL
    Am J Mens Health; 2018 Jan; 12(1):5-13. PubMed ID: 26438468
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incorporating multidimensional patient-reported outcomes of symptom severity, functioning, and quality of life in the Individual Burden of Illness Index for Depression to measure treatment impact and recovery in MDD.
    Cohen RM; Greenberg JM; IsHak WW
    JAMA Psychiatry; 2013 Mar; 70(3):343-50. PubMed ID: 23303512
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ethnicity/race and outcome in the treatment of depression: results from STAR*D.
    Lesser IM; Castro DB; Gaynes BN; Gonzalez J; Rush AJ; Alpert JE; Trivedi M; Luther JF; Wisniewski SR
    Med Care; 2007 Nov; 45(11):1043-51. PubMed ID: 18049344
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functional Impairment and Changes in Depression Subtypes for Women in STAR*D: A Latent Transition Analysis.
    Ulbricht CM; Rothschild AJ; Lapane KL
    J Womens Health (Larchmt); 2016 May; 25(5):464-72. PubMed ID: 26488110
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Brief, unidimensional melancholia rating scales are highly sensitive to the effect of citalopram and may have biological validity: implications for the research domain criteria (RDoC).
    Ostergaard SD; Bech P; Trivedi MH; Wisniewski SR; Rush AJ; Fava M
    J Affect Disord; 2014 Jul; 163():18-24. PubMed ID: 24836083
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An evaluation of the quick inventory of depressive symptomatology and the hamilton rating scale for depression: a sequenced treatment alternatives to relieve depression trial report.
    Rush AJ; Bernstein IH; Trivedi MH; Carmody TJ; Wisniewski S; Mundt JC; Shores-Wilson K; Biggs MM; Woo A; Nierenberg AA; Fava M
    Biol Psychiatry; 2006 Mar; 59(6):493-501. PubMed ID: 16199008
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Depression Subtypes in Predicting Antidepressant Response: A Report From the iSPOT-D Trial.
    Arnow BA; Blasey C; Williams LM; Palmer DM; Rekshan W; Schatzberg AF; Etkin A; Kulkarni J; Luther JF; Rush AJ
    Am J Psychiatry; 2015 Aug; 172(8):743-50. PubMed ID: 25815419
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treating depression after initial treatment failure: directly comparing switch and augmenting strategies in STAR*D.
    Gaynes BN; Dusetzina SB; Ellis AR; Hansen RA; Farley JF; Miller WC; Stürmer T
    J Clin Psychopharmacol; 2012 Feb; 32(1):114-9. PubMed ID: 22198447
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Depression symptom dimensions as predictors of antidepressant treatment outcome: replicable evidence for interest-activity symptoms.
    Uher R; Perlis RH; Henigsberg N; Zobel A; Rietschel M; Mors O; Hauser J; Dernovsek MZ; Souery D; Bajs M; Maier W; Aitchison KJ; Farmer A; McGuffin P
    Psychol Med; 2012 May; 42(5):967-80. PubMed ID: 21929846
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Depression outcomes of Spanish- and english-speaking Hispanic outpatients in STAR*D.
    Lesser I; Rosales A; Zisook S; Gonzalez C; Flores D; Trivedi M; Sciolla A; Luther J; Wisniewski S; Alpert J; Cook I; Rush AJ; Epstein M
    Psychiatr Serv; 2008 Nov; 59(11):1273-84. PubMed ID: 18971403
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predicting relapse with individual residual symptoms in major depressive disorder: a reanalysis of the STAR*D data.
    Sakurai H; Suzuki T; Yoshimura K; Mimura M; Uchida H
    Psychopharmacology (Berl); 2017 Aug; 234(16):2453-2461. PubMed ID: 28470399
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Network analysis of the Quick Inventory of Depressive Symptomatology: Reanalysis of the STAR*D clinical trial.
    Madhoo M; Levine SZ
    Eur Neuropsychopharmacol; 2016 Nov; 26(11):1768-1774. PubMed ID: 27707535
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diurnal mood variation in outpatients with major depressive disorder.
    Morris DW; Trivedi MH; Fava M; Wisniewski SR; Balasubramani GK; Khan AY; Jain S; Rush AJ
    Depress Anxiety; 2009; 26(9):851-63. PubMed ID: 19306304
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Melancholic, atypical and anxious depression subtypes and outcome of treatment with escitalopram and nortriptyline.
    Uher R; Dernovsek MZ; Mors O; Hauser J; Souery D; Zobel A; Maier W; Henigsberg N; Kalember P; Rietschel M; Placentino A; Mendlewicz J; Aitchison KJ; McGuffin P; Farmer A
    J Affect Disord; 2011 Jul; 132(1-2):112-20. PubMed ID: 21411156
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quality of Life and Functioning in Comorbid Posttraumatic Stress Disorder and Major Depressive Disorder After Treatment With Citalopram Monotherapy.
    Steiner AJ; Boulos N; Mirocha J; Wright SM; Collison KL; IsHak WW
    Clin Neuropharmacol; 2017; 40(1):16-23. PubMed ID: 27764051
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Distressing adverse events after antidepressant switch in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial: influence of adverse events during initial treatment with citalopram on development of subsequent adverse events with an alternative antidepressant.
    Katz AJ; Dusetzina SB; Farley JF; Ellis AR; Gaynes BN; Castillo WC; Stürmer T; Hansen RA
    Pharmacotherapy; 2012 Mar; 32(3):234-43. PubMed ID: 22392456
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Escitalopram for severe asthma and major depressive disorder: a randomized, double-blind, placebo-controlled proof-of-concept study.
    Brown ES; Howard C; Khan DA; Carmody TJ
    Psychosomatics; 2012; 53(1):75-80. PubMed ID: 22221724
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quality of Life, Functioning, and Depressive Symptom Severity in Older Adults With Major Depressive Disorder Treated With Citalopram in the STAR*D Study.
    Steiner AJ; Recacho J; Vanle B; Dang J; Wright SM; Miller JS; Kauzor K; Reid M; Bashmi LE; Mirocha J; Danovitch I; IsHak WW
    J Clin Psychiatry; 2017 Jul; 78(7):897-903. PubMed ID: 28858443
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.